No Detail Found!

Effect of Osimertinib on the expression of serum mmp-7 and mmp-9 in patients with non-small cell lung cancer

Author(s)
Nuo Yang Department of Cardio-Thoracic Surgery, the First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi,China
Ruirong Wan Department of Pharmacy, the First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi,China
Lei Dai Department of Cardio-Thoracic Surgery, the First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi,China
Yongyong Wang Department of Cardio-Thoracic Surgery, the First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi,China
Xiang Tan Department of Cardio-Thoracic Surgery, the First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi,China
Mingwu Chen Department of Cardio-Thoracic Surgery, the First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi,China
Jianji Guo Department of Cardio-Thoracic Surgery, the First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi,China
Huafu Zhou Department of Cardio-Thoracic Surgery, the First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi,China
Abstract
The purpose was to investigate the efficacy and safety of Osimertinib in the treatment of advanced non-small cell lung cancer and to analyze its effects on the expression of serum matrix metalloproteinase-7 (MMP-7) and matrix metallo-proteinase-9 (MMP-9). Eighty patients were equally divided into observation and control group. The observation group was given Osimertinib combined with conventional chemotherapy and the other was treated with conventional chemotherapy alone. The short-term efficacy, the levels of serum MMP-7, MMP-9 and adverse reactions were compared. The effectiveness and clinical benefit rate of the observation group were 62.50% and 92.50% respectively, significantly higher than the control group. There was no significant difference in MMP-7 and MMP-9 before treatment however there was a significant difference after treatment, and the serum MMP-7 & MMP-9 levels showed a trend of increasing with decreasing efficacy. After treatment, comparing with control group, serum MMP-7 and MMP-9 levels were significantly lower, the Karnofsky score was significantly higher, and the improvement effect of the quality of life was statistically significant. Besides, the incidence of leukopenia, thrombocytopenia, anemia and gastrointestinal symptoms were significantly lower. In the treatment of patients with advanced non-small cell lung cancer, Osimertinib significantly reduced the expression of serum MMP-7, MMP-9, improved the clinical benefit and quality of life of patients. The clinical efficacy was significant with a high safety.
Publication Details
Page(s) 499-504
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 33, Issue: S1, Year: 2020

Request the full text from PASTIC

Keywords
MMP-9, Osimertinib, Non-small Cell Lung Cancer, MMP-7
References
Ando M,Okamoto I,Yamamoto N,Takeda K,Tamura K,Seto T,Ariyoshi Y,Fukuoka M Y .2006 .Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol., 24(2) : 2549-56.
Attia M,Huet E,Gossard C,Menashi S,Tassoni MC,Martelly I .2013 .Early events of overused supraspinatus tendons involve matrix metalloproteinases and EMMPRIN/CD147 in the absence of inflammation. Am. J. Sport. Med, 41(4) : 908-17.
Banerjee P,Jana S,Chakraborty S,Swarnakar S S,Biochem S .2013 .Inflammation and MMPs in alcohol-induced liver diseases and protective action of antioxidants. , 50(5) : 377-86.
Bo MK,Bae YH,Koh J .2016 .AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR L858R/T790M, in non-small cell lung cancer cells. Invest, 34(4) : 407-15.
Eccles SA .2004 .Parallels in invasion and angiogenesis provide pivotal points for therapeutic intervention. Int. J. Dev. Biol, 48(3) : 583-98.
Rosell Felip E,R Felip E .2008 .Pemetrexed, non-small-cell lung cancer. NSCLC. Ther. Clin. Res. Man., 4(1) : 579-85.
Greig SL .2016 .. Osimertinib: First Global Approval. Drugs, 76(1) : 263-73.
Gridelli C,De MF,Di MM,Cortinovis D,Cappuzzo F,Mok T .2011 .Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Lung Can, 71(1) : 249-257.
Ioannidis G,Souglakos J,Georgoulias V .2013 .Predicting toxicity in advanced lung cancer patients treated with platinum-based chemotherapy. Lun. Can. Man., 2(1) : 281-93.
Kumar VK,Rao JS .2012 .MMP-9 and uPAR regulated glioma cell migration. Cell Adh, 6(2) : 509-512.
Lu S,Cheng Y,Zhou CC,Wang J,Yang JCH,Zhang PH,Zhang XQ,Wang X,Orlando M,Wu YL M .2016 .Meta-analysis of first-line pemetrexed plus platinum treatment in compared to other platinumbased doublet regimens in elderly east asian patients with advanced nonsquamous non-small-cell lung cancer. Clin. Lung Can, 17(3) : e103-12.
Lynch CC,Hikosaka A,Acuff HB,Martin MD,Kawai N,Singh RK,Vargo-Gogola TC,Begtrup JL,Peterson TE,Fingleton B,Shirai T .2005 .MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. , 7(2) : 485-96.
Newby AC .2006 .Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Card. Vas. Res., 69(2) : 614-24.
Rosell R,Molina M A,Costa C,Simonetti S,GimenezCapitan A,Bertran-Alamillo J,Mayo C,Moran T,Mendez P,Cardenal F,Isla D F .2011 .Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin. Can. Res., 17(5) : 1160-68.
Scagliotti G,Hanna N,Fossella F,Sugarman K,Blatter J,Peterson P,Simms L,Shepherd FA .2009 .The differential efficacy of pemetrexed according to NSCLC histology: A review of two Phase III studies. , 14(3) : 253-63.
Wang Z,Duan J,Guo Q .2008 .A phase II clinical trial of celecoxib combined with platinum-based chemotherapy in the treatment of patients with advanced NSCLC as first-line treatment. Chin. J. Lung. Can., 11(1) : 425-30.
Wang Z,Chen R,Wang S,Zhong J,Wu M,Zhao J,Duan J,Zhuo M,An T,Wang Y,Bai H Y .2014 .Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC. , 9(1) : e110780.
Yoshizawa A,Fukuoka J,Shimizu S,Shilo K,Franks TJ,Hewitt SM,Fujii T,Cordon-Cardo C,Jen J,Travis WD .2010 .Overexpression of phospho-eIF4E is associated with survival through AKT pathway in nonsmall cell lung cancer. Clin. Can. Res., 16(1) : 240-248.
Yurdakul A,Akyurek N,Yilmaz S,Karakaya J,Ozturk C .2012 .Prognostic impact of matrix metalloproteinases (MMP-9 and MMP-2) and vascular endothelial growth factor expression in non-small cell lung cancer. Turk. J. Med. Sci., 42(1) : 281-288.
Zhang JG,Wang JJ,Zhao F,Liu Q,Jiang K,Yang GH .2010 .represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin. Chim. Acta., 411(11) : 846-852.
0

Citations

0

Downloads

8

Views